The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
CD44v6: a target for antibody-based cancer therapy
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Cited by
Misra, S., Hascall, V. C., Markwald, R. R., & Ghatak, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00201 · Cited by 830
Aberrant and Alternative Splicing in Cancer
Venables, J. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1910 · Cited by 634
Alternative splicing in disease and therapy
Garcia-Blanco, M. A., Baraniak, A. P., & Lasda, E. L. (2004) · Nature Biotechnology · doi:10.1038/nbt964 · Cited by 527
CD44, a therapeutic target for metastasising tumours
Orian-Rousseau, V. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.024 · Cited by 474
The evolving concept of cancer and metastasis stem cells
Baccelli, I., & Trumpp, A. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201202014 · Cited by 412
Metadata
- Authors
- Heider, K.-H., Kuthan, H., Stehle, G., & Munzert, G.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2004-07-01
- Volume
- 53
- Issue
- 7
- Pages
- 567-579
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2064505748
- Cited by
- 173
- References
- 1
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD44v6: a target for antibody-based cancer therapy. https://app.cochat.ai/papers/10.1007/s00262-003-0494-4
- The paper
- Heider, K.-H., Kuthan, H., Stehle, G., & Munzert, G. (2004). CD44v6: a target for antibody-based cancer therapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-003-0494-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.